Pyridostigmine Bromide Tablets

The Defense Logistics Agency - Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs). Pyridostigmine Bromide Tablets (PB Tablets), USP, 30 MG, Individually Sealed, 210s. NSN 6505-01-178-7903. Tablets shall be in accordance with the specification and requirements of the U.S. Food and Drug Administration and have an FDA approved shelf life of no less than 120 months. The unit of issue for the product is packages. One package shall contain 10 immediate containers in protective sleeves, each containing 21 individually sealed tablets (210 tablets), together with a desiccant, as specified, constitutes one unit.

DLA Troop Support has an annual estimated requirement for Pyridostigmine Bromide Tablets of 27,000 PG’s with a one (1) base year with four (4) one year option periods . However, the quantities may increase or decrease as the Services requirements change. PB Tabs shall be delivered to the Defense Distribution Center (DDC) in Norfolk, VA.

This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make award, or pay any cost associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.

*** Currently Marked Pyridostigmine Bromide Tablets ***

If your firm currently markets Pyridostigmine Bromide Tablets, please provide information with respect to the following:

1. Place of Manufacture


2. Estimated Annual Capacity


3. FDA Registration information


4. Product Name and description including description of any special features


5. Current unit sales price


6. Estimated inventory level and storage requirements


7. Delivery days for this item and earliest product available time


8. Country of origin for API


9. Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).

***New Product Under Development***

For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture products described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.

Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Pyridostigmine Bromide Tablets. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.

Your response to this RFI may be submitted electronically in PDF format and emailed to Contracting Specialist Rosbert.Jones@dla.mil.